Status:
SUSPENDED
Intranasal TXA for Anterior Epistaxis in the Emergency Department
Lead Sponsor:
Mercy Health Ohio
Conditions:
Epistaxis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The objective of this study is to evaluate the efficacy of and patient satisfaction with the use of intranasal tranexamic acid (TXA) for anterior nosebleeds in the emergency department (ED).
Detailed Description
Pledget soaked in either saline or TXA will be applied to the bleeding nare of the patient presenting with anterior epistaxis. After fifteen minutes, the pledget will be removed and patient reassessed...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- • Patients 18 years and older with anterior epistaxis
- Exclusion criteria:
- Patients with inability to give consent
- Patients without a working telephone number
- Patients lacking the mental capacity to make their own decisions
- Patients with posterior epistaxis
- Epistaxis following major trauma
- Patients with known bleeding disorder like hemophilia and thrombocytopenia
- Prisoners
- Patients hemodynamically unstable
- Pregnant patients
- Patients with a known allergy to TXA
- Patients with a visibly bleeding vessel
- Those recently post-op nasal/sinus surgery (within ten days) will also be excluded
Exclusion
Key Trial Info
Start Date :
November 7 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2021
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT04054687
Start Date
November 7 2019
End Date
May 1 2021
Last Update
September 11 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
St Elizabeth Boardman Hospital
Boardman, Ohio, United States, 44512
2
St Elizabeth Youngstown
Youngstown, Ohio, United States, 44504